Pfizer Zithromax adds new regimen/strength
This article was originally published in Pharmaceutical Approvals Monthly
Executive SummaryOn May 24, FDA approves three-day dosing regimen of Pfizer's Zithromax (azithromycin) with new 500 mg tablet for treatment of acute bacterial exacerbations of chronic obstructive pulmonary disease due to S. pneumoniae, H. influenzae and M. catarrhalis. Labeling previously recommended a five-day regimen for the indication. Zithromax also is available in 250 mg tabs and capsules, 600 mg tabs, oral solution and an I.V. for
You may also be interested in...
Abbott is encouraged by results from two studies of its Proclaim XR neurostimulation system for chronic pain, presented at the annual North American Neuromodulation Society (NANS) meeting in Las Vegas. See what Steven Falowski of Neurosurgical Associates of Lancester in Pennsylvania said about it here.
While disappointing result will probably put an end to single-drug plans in ovarian cancer, the blockbuster anti-PD-1 immunotherapy remains in combination development for the indication.
According to the plaintiff, Unilever’s Pond’s Rejuveness Anti-Wrinkle Cream is defective insofar as tested product has been found to contain unlabeled mercury, constituting negligence that has resulted in user injuries. The plaintiff seeks certification of a transnational class and compensatory and punitive damages, among other relief.